v3.26.1
Segment Information - Summary of Reconciliation of Reported Operating Expenses to Net Loss Under the Significant Expenses Principle (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Research and development:    
Indirect expenses $ 1,891 $ 2,013
Personnel-related expenses 6,839 7,451
Total research and development expenses 15,598 19,435
Selling, general and administrative 5,222 5,324
Total operating expenses 20,820 24,759
Other income, net 30,038 1,024
Net Income (Loss) 9,218 (23,735)
Revita Direct Program Expenses    
Research and development:    
Total research and development expenses 4,965 6,754
Rejuva Direct Program Expenses    
Research and development:    
Total research and development expenses $ 1,903 $ 3,217